{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:13:11Z","timestamp":1792451591661,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-5-075"],"award-info":[{"award-number":["2021-I2M-5-075"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2019RU067"],"award-info":[{"award-number":["2019RU067"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073404"],"award-info":[{"award-number":["82073404"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772693"],"award-info":[{"award-number":["81772693"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102898"],"award-info":[{"award-number":["82102898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ymthe.2022.08.021","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T03:30:45Z","timestamp":1662089445000},"page":"134-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":221,"title":["CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Guoqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-6358","authenticated-orcid":false,"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.08.021_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.021_bib2","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2022.08.021_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A review of glioblastoma immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-021-01161-4","article-title":"Engineered T\u00a0cells: CAR T\u00a0cell therapy and beyond","volume":"24","author":"Johnson","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ymthe.2022.08.021_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.08.021_bib6","doi-asserted-by":"crossref","first-page":"662064","DOI":"10.3389\/fnins.2021.662064","article-title":"CAR T\u00a0cell-based immunotherapy for the treatment of glioblastoma","volume":"15","author":"Maggs","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2022.08.021_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.08.021_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T\u00a0cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1535-7163.MCT-06-0709","article-title":"Characterization of the CCL21-mediated melanoma-specific immune responses and in\u00a0situ melanoma eradication","volume":"6","author":"Novak","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2022.08.021_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2008.04.050","article-title":"The role of CXC chemokines and their receptors in cancer","volume":"267","author":"Vandercappellen","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2022.08.021_bib11","doi-asserted-by":"crossref","first-page":"594609","DOI":"10.3389\/fimmu.2020.594609","article-title":"Cytokine and chemokine signals of T-cell exclusion in tumors","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib12","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib13","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.4049\/jimmunol.0803340","article-title":"IL-7 promotes CXCR3 ligand-dependent T\u00a0cell antitumor reactivity in lung cancer","volume":"182","author":"Andersson","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","article-title":"Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer","volume":"138","author":"Mlecnik","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2022.08.021_bib15","first-page":"14725","article-title":"Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.08.021_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.021_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.08.021_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.08.021_bib22","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1158\/1078-0432.CCR-18-1627","article-title":"Brain tumor microenvironment and host state: implications for immunotherapy","volume":"25","author":"Tomaszewski","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in\u00a0vivo","volume":"31","author":"Di Paolo","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.08.021_bib24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2009.135","article-title":"The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon","volume":"20","author":"Prestwich","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.08.021_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/BST20150254","article-title":"Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells","volume":"44","author":"Ager","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymthe.2022.08.021_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1172\/JCI82976","article-title":"A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer","volume":"127","author":"Berlato","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.021_bib27","article-title":"Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.021_bib28","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-0328","article-title":"Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a phase I study","volume":"26","author":"Zamarin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2003.10.003","article-title":"The significance of cancer cell expression of the chemokine receptor CXCR4","volume":"14","author":"Balkwill","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2022.08.021_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-15-1926","article-title":"Cancer cell dissemination and homing to the bone marrow in a zebrafish model","volume":"76","author":"Sacco","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/416094a","article-title":"Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position","volume":"416","author":"Reif","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.021_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.021_bib34","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.169.5.2461","article-title":"The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7","volume":"169","author":"Szanya","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib35","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T\u00a0cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib36","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1158\/0008-5472.CAN-11-1466","article-title":"Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control","volume":"71","author":"Hong","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI1422","article-title":"The chemokine receptors CXCR3 and CCR5 mark subsets of T\u00a0cells associated with certain inflammatory reactions","volume":"101","author":"Qin","year":"1998","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.021_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1074\/jbc.M209470200","article-title":"Structure-function relationship between the human chemokine receptor CXCR3 and its ligands","volume":"278","author":"Clark-Lewis","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.08.021_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2022.08.021_bib40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T\u00a0cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.08.021_bib41","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T\u00a0cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib42","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1084\/jem.187.12.2009","article-title":"Interferon-inducible T\u00a0cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T\u00a0cells through selective high affinity binding to CXCR3","volume":"187","author":"Cole","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.08.021_bib43","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T\u00a0cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib44","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1038\/s41598-018-23099-7","article-title":"Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer","volume":"8","author":"Araujo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.08.021_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051477","article-title":"Inhibition of the CCL5\/CCR5 Axis against the progression of gastric cancer","volume":"19","author":"Aldinucci","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.08.021_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","article-title":"CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer","volume":"42","author":"Pervaiz","year":"2019","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.ymthe.2022.08.021_bib47","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41598-018-19643-0","article-title":"CCR5\/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells","volume":"8","author":"Singh","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.08.021_bib48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2478\/raon-2019-0057","article-title":"Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme","volume":"53","author":"Kranjc","year":"2019","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib49","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.08.021_bib51","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: from infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib53","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib54","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ni.f.213","article-title":"Orchestrating the orchestrators: chemokines in control of T\u00a0cell traffic","volume":"9","author":"Bromley","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.cji.0000165355.26795.27","article-title":"The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in\u00a0vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis","volume":"28","author":"Hensbergen","year":"2005","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2022.08.021_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.0300-9475.2004.01391.x","article-title":"A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in\u00a0vivo","volume":"59","author":"Hamilton","year":"2004","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00262-006-0190-2","article-title":"Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture","volume":"56","author":"Berencsi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2022.08.021_bib58","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jlb.61.3.246","article-title":"Mig and IP-10: CXC chemokines that target lymphocytes","volume":"61","author":"Farber","year":"1997","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/imm.12293","article-title":"CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model","volume":"143","author":"Oghumu","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2022.08.021_bib61","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T\u00a0cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.08.021_bib62","first-page":"817","article-title":"Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas","volume":"3","author":"M\u00e9nard","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in\u00a0vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.021_bib65","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/jcp.24260","article-title":"Tumor associated macrophages and neutrophils in tumor progression","volume":"228","author":"Galdiero","year":"2013","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2022.08.021_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in glioblastoma microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2022.08.021_bib67","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2022.08.021_bib68","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/JIR.S357787","article-title":"Systematic analysis of chemokines reveals CCL18 is a prognostic biomarker in glioblastoma","volume":"15","author":"Gao","year":"2022","journal-title":"J.\u00a0Inflamm. Res."},{"key":"10.1016\/j.ymthe.2022.08.021_bib69","doi-asserted-by":"crossref","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3","volume":"290","author":"Ahmed","year":"2015","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:46:42Z","timestamp":1778816802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622005500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525001622005500"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.021","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}